| 货号 | CAS号 | 价格 |
|---|---|---|
| C153431-100mg | 117048-59-6 | ￥2,299.00 |
| C153431-1g | 117048-59-6 | ￥11,999.00 |
| C153431-250MG | 117048-59-6 | ￥4,399.00 |
| C153431-25MG | 117048-59-6 | ￥739.00 |
| C153431-5mg | 117048-59-6 | ￥239.00 |
| 敏感性 | 对光线敏感 |
| 溶解性 | DMSO: >10 mg/mL |
| 存贮条件 | 储存温度-20°C |
| 生化机理 | Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol. |
| 别名 | (Z)-2-甲氧基-5-(3,4,5-三甲氧基苯乙烯基)苯酚;3'-羟基-3,4,4',5-四甲氧基-顺-芪 ;(Z)-2-Methoxy-5-(3,4,5-trimethoxystyryl)phenol;3'-Hydroxy-3,4,4',5-tetramethoxy-cis-stilbene;1-(3,4,5-Trimethoxyphenyl)-2-(3′-hydroxy-4′-methoxyphenyl) ethane 3,4,5-trimethoxy-3′-hydroxy-4′-methoxystilbene;2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol,;CA4 |
